Glenmark gets USFDA approval for its Fingolimod capsules: Glenmark Pharmaceuticals received the USFDA’s[1] approval for manufacturing the generic version of the 0.5 mg Gilenya capsules. Novartis Pharmaceuticals Corporation held the patent rights for Gilenya capsules and on expiry of this patent, other drug firms had begun to apply to the USFDA for marketing the generic […]
USFDA revokes the special status given to Hydroxychloroquine for treating Covid-19 In March 2020, the US[1] president, Donald Trump began to advocate the use of Hydroxychloroquine and azithromycin for treating Covid-19. His persuasive speech backed up by his claim of taking Hydroxychloroquine regularly won the trust of the entire country. This subsequently increased the demand
Gilead signs licensing pacts with four more drug firms for manufacturing Remdesivir Pharma news – June 20: Gilead Sciences Ltd has recently been signing pacts with various drug firms for the manufacture and marketing of its antiviral drug, #Remdesivir. This drug had received emergency use authorization (EUA) in many countries for treating Covid-19. This decision
Indian Government lifts ban on the export of Hydroxychloroquine Pharma news – June 11: On 25 March 2020, the Indian government banned the export of numerous drugs. The anti-malarial drug, Hydroxychloroquine, was also included in this list. However, there were some relaxations allowed for exporting Hydroxychloroquine since many believed it was capable of treating Covid-19.
